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Abstract 
Starting from the histamine role in the renal haemodynamic, over time, spare evidence suggested a 
wider range of action on renal function and renewed the interest on the pathophysiological role of 
histamine in the kidney. This review intends to provide an up-to-date focus on this topic. According 
to the intrarenal production of histamine and the renal presence of its receptors, the histaminergic 
machinery appears to be well suited. The distribution of histamine receptors supports their differential 
effects but do not exclude the redundancy of H1 and H2 receptors in renal haemodynamics, the 
complementary role of H1 and H4 receptors in renal filtration and reabsorption, and the dichotomy 
between local and neuronal H1 and H3 receptors. Experimental models of renal diseases rise the 
hypothesis of new therapeutic approaches histamine based. A complete elucidation of the influence 




Keywords: renal pathophysiology, histamine, histamine receptors, kidneys, renal disease 
Abbreviations: alpha-HH = alpha-hydrazinohistidine; AQP = aquaporin; DAO = diaminoxidase; 
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decarboxylase; HNMT = histamine-N-methyltransferase; Kf = ultrafiltration coefficient; OCT = 
organic cation transporter; PA = puromycin aminoglycoside; TGF = transforming growth factor; ZO 
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Douglas (1971) wrote “the core of the matter is that, while the autacoids possess an astonishingly 
wide range of pharmacological activities […], there are comparatively few instances where a 
physiological role can be stated with assurance”. Compared to its pleiotropic effects, the therapeutic 
strategies based on histamine targeting are very few: H1 receptor  antihistamines for the treatment of 
allergy (Simons and Simons, 2011), H2 receptor antagonists for peptic ulcer (Singh et al., 2018) and 
the H3 receptor inverse agonist pitolisant for narcolepsy (Kollb-Sielecka et al., 2017).  
Other effects exerted by histamine cannot be translated to therapeutic approaches till the contribute 
of the amine to a specific pathophysiological event is not functionally weighed. Therefore, looking 
at the kidney, the goal is to define the role of the amine in the renal pathophysiology. The evidence 
for histamine playing a role in this organ has been scanty investigated over the years. In renal 
plethysmografic studies (Dale and Laidlaw, 1910; Dale and Richards, 1918) histamine injection 
evoked the renal arteriolar constriction. Renal arteriolar constriction triggers the alteration of the 
glomerular hydrostatic pressure and causes the reduction of the renal blood flow. These events 
culminate in the modulation of the glomerular filtration rate (GFR): reduced by renal afferent 
arteriolar constriction and increased by renal efferent arteriolar constriction (Dalal and Sehdev, 2018). 
The changes induced by the amine on the renal circulation could account for the drop in both urea 
and creatinine clearance observed after histamine injections in human subjects with various 
cardiovascular and renal pathologies (Bjering, 1937). These acute effects were observed after a high 
loading dose of histamine (1 mg s.c.) and were accompanied by a simultaneous fall in blood pressure, 
therefore might be due to a systemic vascular event elicited by the amine. However, Bjering (1937) 
stressed that it is reasonable to assume that histamine affects both the glomerular and tubular function. 
Indeed, an increase in protein concentration causes the rise of the glomerular capillary oncotic 
pressure with a consequent decrease in GFR (Dalal and Sehdev, 2018). It was noted that in dogs 
histamine injection was able to acutely induced albuminuria (1 day after histamine load), and 
degenerative tubules changes after 7 days (Bjering, 1937). Anyway, since that time, histamine's 
contribution to renal function was always linked to its vasoactive properties, relegating histamine to 
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the sole role of haemodynamic regulation (Pini et al., 2016b). Some time later, between the ‘70s-
‘80s, the possibility that histamine played a role in renal immune-mediated diseases was explored, 
but no conclusive data was provided. In the last decade the discovery of the presence of all the known 
histamine receptors [H1-4 receptors; as designated by International Union of Pharmacology – 
IUPHAR; Alexander et al., 2017)] on residential renal cells renewed the interest for the possible role 
of histamine in renal function. Therefore, this review intends to provide an up-to-date focus on data 
supporting the possible pathophysiological role of histamine in the mammalian kidney. 
The histaminergic machinery in the kidneys 
The presence of the histamine metabolic enzymes diaminoxidase (DAO, whose metabolic product is 
the imidazole-4-acetaldehyde) (Wolvekamp and de Bruin, 1994) and histamine-N-methyltransferase 
(HNMT, producing the N-methyl-histamine) (Brown et al., 1959) in the cytoplasm of renal residential 
cells highlights that histamine is handled by the kidney, but the source of the amine in this organ has 
been the subject of some discussion. Histamine enters the intracellular system through active transport 
by the organic cation transporter (OCT)-2 (Ogasawara et al., 2006), expressed exclusively in renal 
tissue (Aoki et al., 2008). However, the hypothesis that histamine in the kidney could derive only 
from the circulatory system may be retained unlikely. A first observation in keeping with this theory 
is the ipsilateral histamine synthesis following the infusion of L-histidine, the aminoacid precursor of 
histamine, into the renal arteries of dogs (Lindell and Schayer, 1958). Nevertheless, the histidine 
decarboxylase (HDC) enzyme, which is responsible for histamine synthesis, was purified from the 
kidneys of thyroxine-treated mice in 1986 (Martin and Bishop, 1986). A significant increase in 
histamine content in the human glomerular suspension was observed when the isolated glomeruli and 
tubules were incubated with L-histidine 1mM but not with D-histidine 1mM, used as negative control. 
The challenge of isolated glomeruli with the HDC inhibitor brocresine blocked the accumulation of 
histamine evoked by L-histidine (Sedor and Abboud, 1984). It could be questioned that brocresine is 
not selective to HDC, being able to inhibit also the nonspecific aromatic L-amino acid decarboxylase 
(Hakanson and Liedberg, 1972), as well as to affect histamine catabolism (Binder and Sewing, 1973). 
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However, a demonstration of the presence of specific HDC enzyme in the glomeruli came already 
from Heald and Hollis (1976) who purified a glomerular enzyme with an apparent Michaelis-Menten 
constant (Km) for histidine of 240 µM and a optimal pH of 6.2 for histidine 10 mM. On the contrary, 
the nonspecific aromatic L-amino acid decarboxylase has a higher Km (100-10 mM) and an optimum 
pH independent from histidine concentration. 
The observation by Sedor and Abboud (1984) was the first clear evidence of the production and 
presence of histamine in the kidneys despite the absence of mast cells, the professional source of 
histamine, in human glomeruli (Li et al., 2007). Mast cells have been found to be present in very low 
constitutive number in the whole kidney (Li et al., 2007). Despite the number of mast cells, kidneys 
have been reported to contain a concentration of histamine ranging from about 2 pmol/mg organ 
weight (5- to 9-week-old mice) to about 5 pmol/mg organ weight (10- to 14-week-old mice) 
(Zimmermann et al., 2011). Notably, these values are comparable with previously reported amounts 
(Burtin et al., 1982; Sedor and Abboud, 1984) and are far above circulating levels in humans (< 10 
nM). This content was paralleled by levels of the histamine metabolite, N-methylhistamine, in urine 
(Zimmermann et al., 2011). Collectively, this evidence points out the possibility of a local intrarenal 
production and secretion of histamine. The wide distribution of HDC enzyme other than in mast cells, 
is now well recognised. It is ubiquitously expressed in the proximal tubules of both mice and humans, 
both in foetuses and adults (Morgan et al., 2006). Notably, the enzyme expression is up-regulated in 
physiological/adaptive processes. Indeed, HDC is over-expressed in the kidneys of pregnant mice, 
especially in the superficial cortical zone. These findings suggest that intrarenal produced histamine 
may increase renal blood flow and recruit superficial cortical nephrons during pregnancy (Morgan et 
al., 2006). However, histamine is also known to exert mitogenic effects, thus potentially contributing 
to the lengthening of the proximal tubule (Morgan et al., 2006). 
Whereas the presence of intrarenal produced histamine in the kidneys is now established and 
documented, which histamine receptor is present and where it is located is still a matter for debate. 
Indeed, the immunological detection of histamine receptors is biased by antibodies, whose specificity 
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is often questioned. H1 receptor and H2 receptor expression on renal vessels has long been established 
(Banks et al., 1978). More recently, an in vitro pharmacological approach performed on both primary 
and immortalised selected renal cell types from different mammals (Table 1), allowed to identified 
in the nephron and collecting ducts not only the H1 receptor and H2 receptor, but also the more recently 
discovered H3 receptor and H4 receptor (Rosa et al., 2013; Pini et al., 2015; Veglia et al., 2015; Veglia 
et al., 2016). A differential distribution of histamine receptors can be observed in the nephron and 
collecting duct (Figure 1 and Table 1). H1 receptor is the most prevalent, as it is localised on both the 
glomerular and tubular levels. It was described in the glomerulus for the first time in 1985, when the 
H1 receptor antagonist diphenhydramine (100 µM) suppressed the contractile effects evoked by 
histamine (5 µM to 100 µM) in a primary culture of mesangial cells from Sprague-Dewley rats (Sedor 
and Abboud, 1985). Only H1 receptor and H2 receptor were known at that time, and the presence of 
H2 receptor was demonstrated in the same cells via the measurement of the accumulation of the second 
messenger cAMP following histamine challenge. The H2 receptor antagonists cimetidine (Sedor and 
Abboud, 1985) and metiamide (Torres et al., 1978) blunted histamine-induced second messenger 
production. More recently, a better insight of glomerular histamine receptor presence was provided. 
Four different cell types can be distinguished within the glomerulus: glomerular endothelial cells, 
podocytes, mesangial cells and parietal epithelial cells. Podocytes are the most differentiated of these 
cells and are a crucial component of the glomerular filtration barrier. H1 receptor expression on human 
immortalised podocytes was demonstrated by complementary immunohistochemical and 
pharmacological approaches (Veglia et al., 2016). The confocal analysis revealed that in human 
podocytes only H1 receptor is localised on the cell membrane. H1 receptor expression was confirmed 
by the saturation binding analysis (Veglia et al., 2016). Moreover, histamine challenge evoked a 
sigmoidal dose-dependent increase in IP3, the second messenger involved in the H1 receptor singling 
pathway, but not in cAMP, downstream signal of the histamine receptors (Veglia et al., 2016).  
The presence of H1 receptor has also been demonstrated in both the proximal and distal tubules with 
a similar experimental approach using human primary and immortalised tubular epithelial cells 
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(TECs) from the renal cortex and the proximal tubular epithelial cell line HK-2 (Veglia et al., 2015). 
This study demonstrated also that H2 receptor coexists with H1 receptor in the distal tubules (Veglia 
et al., 2015). Even the H4 receptor and H3 receptor subtypes have been found in the kidneys. By 
immunolabeling and gene expression analyses, the presence of H4 receptor has been revealed. H4 
receptor shows partial species-dependent distribution (Table 1), with rats expressing it mostly in the 
ascending limb of Henlé's loop (Rosa et al., 2013), and humans and mice mostly on the proximal 
tubule (Veglia et al., 2015; Pini et al., 2018). The interspecies variability is in line with previous data 
on H4 receptor receptor expression (Liu et al., 2001). 
The data by immunoassay were confirmed at least in humans by the functional assay evaluating 
cAMP accumulation following histamine challenge alone or with histamine receptor selective 
antagonists (Veglia et al., 2015). H3 receptor has surprisingly been found on the principal cells of the 
collecting duct, both in humans (Veglia et al., 2015) and in rats (Pini et al., 2015). Again the data 
were obtained by both immunodetection and gene expression in both ex-vivo and in-vitro studies (Pini 
et al., 2015; Veglia et al., 2015) and were confirmed in vitro on human renal cells (Veglia et al., 
2015), as described above. 
The role of histamine in the kidneys 
Despite high amount of histamine in kidneys, only few independent data provide evidence of the role 
that histamine plays in renal haemodynamic and, even less, suggest that it has effects far beyond its 
vasoactive properties. The data currently available on the role of histamine on renal function do not 
allow a clear differentiation between the physiological and the pathophysiological effects of 
histamine and its role in renal diseases. Similarly, is not possible to really discriminate between the 
effect of the extrarenal and the intrarenal produced histamine. Indeed, the possible role of the amine 
on kidney function mostly derives from studies in which histamine has been exogenously 
administered.  
Figure 2 summarises the proposed effects of histamine on renal function and the potential contribution 
of the receptor subtypes. The relative contribution is mostly due to the localisation of the histamine 
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receptors on different renal cell types (Figure 1) and is consistent with the pharmacological 
characterisation of the histaminergic system in various mammals. Changes in renal circulation have 
been observed both in normotensive and hypertensive subjects without any history of renal disease 
challenged with histamine s.c. in the 0.3-0.5 mg range. Both groups showed an elevation in filtration 
fraction and a reduction in renal plasma flow that were ascribed to the efferent arteriolar constriction, 
observed in the majority of them (Reubi and Futcher, 1949). On the other side, a higher dose of 
histamine (1 mg s.c.) caused a fall in blood pressure and a drop in creatinine and urea clearance 
(Bjering, 1937). It is known that renal blood flow autoregulation is a defensive mechanism that 
protects the kidney from elevation in arterial pressure and that allows the kidney to maintain a 
relatively constant GFR (Burke et al., 2014). The experimental data are in favour of an active role of 
at least the extrarenal histamine in regulating GFR, eventually as a possible effector of the renal blood 
flow autoregulation via H1 receptor (Banks et al., 1984). Indeed, after the intrarenal infusion of 
chlorpheniramine 10-5 mol/min or other H1 receptor antagonists/inverse agonists, with a variety of 
chemical structures (terfenadine, diphenhydramine and mepyramine), attenuated the hyperaemia 
evoked by aortic clamping. Furthermore, a drop in the GFR was measured in parallel (Banks et al., 
1984). A similar effect was observed when H1 receptor antagonists were used to counteract histamine 
infusion-induced renal vasodilation (Banks et al., 1978). Interestingly, this study, in accordance with 
the one by Campbell and Itskovitz (1976) on isolated blood-perfused canine kidneys, failed to 
demonstrate the involvement of H2 receptor. However, other reports have published opposing results, 
in which ranitidine (Laight et al., 1995) and cimetidine, but not tripelennamine (Radke et al., 1985), 
blunted histamine-induced vasodilation.  
Despite contrasting evidence was provided for the relative contribute of H1 receptor and H2 receptor 
in vasodilation, H2 receptor has been associated with histamine-induced renin release. Histamine and 
dimaprit, at that time thought to be an H2 receptor agonist, induced a significant increase in renin 
release in dogs, while the H1 receptor agonist 2-pyridylethylamine had no effect (Gerber and Nies, 
1983). Similar conclusions were reached by ex vivo studies on isolated perfused rat kidneys. In this 
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model histamine induced renin release in a concentration range 0.5-10 µM, and vasodilation appears 
only at 100 µM. The H2 receptor antagonist ranitidine inhibited the renin release induced by 
histamine. In this study the H1 receptor agonist 2-pyridylethylamine demonstrated a low stimulatory 
activity, but only at 10 µM, a dose at which partial H2 receptor agonism was shown (Schwertschlag 
and Hackenthal, 1982). cAMP accumulation, evoked by H2 receptor stimulation in cultured rat 
mesangial cells (Sedor and Abboud, 1984), was hypothesised to be the underling mechanism. Indeed, 
any increase in cAMP in renin-secreting cells, such as juxtaglomerular cells, has been reported to 
stimulates renin secretion (Castrop et al., 2010). Therefore, on the basis of the role of the renin-
angiotensin-system in vasoconstriction, histamine can contribute to the efferent arteriolar 
constriction, at least via the H2 receptor-renin axis.  
Due to the role of the sympathetic nerve activity in renal haemodynamic, the noradrenergic 
transmission was the other mediator of vasoconstriction for which an interplay with histamine has 
been investigated. The possibility that indirect effects could involve the noradrenergic transmission 
was discounted after negative results were obtained in an atenolol 1 µM infusion test. However, the 
histaminergic system may be involved in the regulation of renal noradrenergic neurotransmission, 
like in the uterus (Montesino et al., 1995). Lateral cerebral ventricular injection of histamine in 
anaesthetised rats demonstrated opposite effects on renal sympathetic nerve activity, in a dose-
dependent manner: 100 nM suppressed and 100 mM stimulated the renal sympathetic nerve activity 
(Tanida et al., 2007). These effects suggest that the renal noradrenergic neurotransmission can be 
affected by the central histaminergic system. H1 receptor and H3 receptor were both implicated, with 
H1 receptor involved in the high-dose effects of histamine, and the H3 receptor involved in the low-
dose effects, consistently with the differential affinity of the two receptors for the natural ligand 
[histamine pki reported for H1 receptor is 4.7 – 5.9 and for H3 receptor is 7.8 - 8.3 (Alexander et al., 
2017)]. Nevertheless, in anaesthetised dogs, following renal nerve stimulation (0.5–2.0 Hz) a 
decrease in urine flow and urinary sodium excretion and an increase in norepinephrine overflow rate 
were observed. These effects were reduced by intravenous infusion of the H3 receptor agonist (R)-
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alpha-methylhistamine (1 µg/kg/min), while the administration of the H3 receptor antagonist 
thioperamide (5 µg/kg/min) evoked an antidiuretic effect and increased the norepinephrine overflow 
rate (Yamasaki et al., 2001).  
These effects were ascribed to a possible localisation of the H3 receptor on renal noradrenergic nerve 
endings. However, data obtained from rats and humans indicated that H3 receptor are present in the 
resident epithelial cells of the collecting duct and that they are colocalised with the vasopressin water 
channel aquaporin (AQP)-2 (Pini et al., 2015; Veglia et al., 2015). This localisation renews interest 
in histamine's effect on diuresis. A role for central histamine in regulating diuresis has, in fact, been 
postulated. Histamine was found to depolarise supraoptic neurons that contain vasopressin, causing 
vasopressin release from axonal endings in the neurohypophysis (Selbach and Haas, 2008). High 
doses of histamine (25-500 µg i.c.v.) have been observed to elicit a dose-dependent antidiuretic 
response with a concomitant rise in blood vasopressin in dogs (Bhargava et al., 1973), although 
tachifilaxis occurred after four doses of histamine 400 µg i.c.v. Mepyramine 5 mg i.c.v. prevented 
these effects. H3 receptor had not yet been discovered at the time of this study, and its potential 
contribution has never been investigated. Nevertheless, its colocalisation with AQP-2 suggests that 
H3 receptor and AQP-2 may cooperate in the vasoprssin response of the principal cells in the 
collecting duct. Although there is evidence for an antidiuretic effect of histamine (Dale and Laidlaw, 
1910; Dale and Richards, 1918; Reubi and Futcher, 1949; Blackmore and Cherry, 1955), there is also 
contrasting evidence to suggest that histamine does not affect urine outflow (Campbell and Itskovitz, 
1976), or even increase water excretion (Sinclair et al., 1974a; Banks et al., 1978; Ichikawa and 
Brenner, 1979). Similarly, conflicting data also exist on the histamine receptor subtype involved. 
Banks et al. (1978) demonstrated that histamine infusion in dogs (1 µg/min per kg) increased urine 
outflow; dimaprit produced a similar effect and the 2-pyridylethylamine reduced the urinary flow 
rate. These data led to the hypotheses that H2 receptor has an active role in water excretion; however, 
we must remember that dimaprit is not an H2 receptor agonist, thought to acts on both H2 receptor 
and H4 receptor (Lim et al., 2009), now has been classified as H3 receptor [pki = 6.1 (Alexander et 
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al., 2017)] and H4 receptor agonist [pki = 4.9 - 6.5 (Alexander et al., 2017)]. In vivo experimental 
models of renal disease with polyuric phenotype, such as diabetic nephropathy, demonstrated that 
pre-treatment with the H4 receptor antagonist JNJ-39758979 reduces the urine outflow of diabetic 
animals in a dose-dependent manner (Pini et al., 2018). Convergent evidence comes from 
unpublished data demonstrating the involvement of H4 receptor in the AQPs pattern of expression 
(Pini, 2018, unpublished data; Verta, 2018, unpublished data). Moreover, the pre-treatment of animals 
with the H1 receptor antagonist tripelennamine has been shown to significantly reduce renal responses 
to histamine infusion, including diuresis (O'Brien and Williamson, 1971). Accordingly, polyuria has 
been reduced by the administration of (R)-cetirizine at 0.5 mg/kg/day in a model of diabetic 
nephropathy in rats (Anbar et al., 2016).  
H1 receptor was found to be correlated with a decrease in the ultrafiltration coefficient (Kf) induced 
by histamine (Ichikawa and Brenner, 1979). These data are consistent with the localisation of H1 
receptor on podocytes (Veglia et al., 2016). Interestingly, it has been demonstrated that histamine 
affects the disruption of cell-to-cell contact, via H1 receptor activation, in an in vitro model of human 
immortalised podocytes. In particular, histamine was found to downregulate the expression of two 
key molecular components of the slit diaphragm, zonula occludens (ZO)-1 and P-cadherin, leading 
to a dose- and time-dependent efflux of albumin. Chlorpheniramine, at 10 µM, was able to restore 
junctional integrity (Veglia et al., 2016). These data are consistent with the theory that histamine 
affects the glomerular pore density with a reduction in total filtration surface area (Ichikawa and 
Brenner, 1979). Nonetheless, histamine i.p. injection at 0.5 mg/kg has been observed to cause foot 
processes loss in fasting rats (Gurgen et al., 2013). These glomerular changes correlate with the 
filtration capacity of the kidneys and affect creatinine and urea clearance. In fact, the effect of H2 
receptor antagonists on creatinine clearance has been extensively studied, and cimetidine has been 
reported to significantly decrease this parameter after 7 days of treatment. This effect is not a class-
effect as it was not reported for other H2 receptor antagonists, such as famotidine (Ishigami et al., 
1989), and is therefore histamine-independent. However, in vivo models of diabetic nephropathy in 
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mice and rats have demonstrated that both (R)-cetirizine (Anbar et al., 2016) and JNJ-39758979 (Pini 
et al., 2018) dramatically restored creatinine clearance in diabetic animals. 
Histamine challenge may be directly responsible for the appearance of albuminuria and proteinuria 
(Bjering, 1937). Interestingly, H1 receptor antagonism has been reported to reduce the degree of 
proteinuria in an experimental model of glomerular nephritis (Bolton et al., 1974) and in diabetes, 
where also an amelioration of albuminuria has also been reported (Anbar et al., 2016). These effects 
are consistent not only with the vascular events associated with histamine receptors, but also with the 
localisation of H1 receptor on glomeruli, and, more precisely, on podocytes. Indeed, the reduction in 
filtration area, caused for instance by fenestration and podocyte loss, is a direct contributor to hyper-
filtration and the consequent albuminuria (Nagata, 2016). However, glomerular hyper-filtration could 
be also triggered by hyper-reabsorption at the proximal tubule, through the decreases of electrolyte 
load to the macula densa, causing an increase in the colloid osmotic pressure of the glomerular 
capillaries (Palatini, 2012). The proximal tubules, where both H1 receptor and H4 receptor (Figure 1) 
are present, are specialised for albumin and protein reabsorption. In particular, the megalin/cubilin 
pathway mediates albumin reabsorption. Interestingly, the H4 receptor antagonist JNJ-39758979 has 
been found to prevent megalin loss in a model of experimental diabetic nephropathy (Pini et al., 
2018). The dysregulation of the reabsortive process at the different levels of the nephron may account 
for the excretion of electrolytes, particularly sodium, excretion induced by histamine via H1 receptor 
(Sinclair et al., 1974b; Banks et al., 1978; Ichikawa and Brenner, 1979; Gerber and Nies, 1983; Laight 
et al., 1995). Furthermore, a potential role for H4 receptor should be considered, even if it has yet to 
be investigated.  
Despite the evidence of functional effects of histamine in the kidney, the actual relevance of the 
contribute of this amine cannot be conclusive demonstrated. Currently, the experimental data are in 
favour of at least an additive role. 
Histamine and renal disease 
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The role of histamine in renal disease can be extrapolated in accordance with the above-reported 
analysis. Moreover, the relative contribution of each histamine receptor reflects their distribution, 
with histamine triggering both degenerative glomerular and tubular changes (Bjering, 1937; Gurgen 
et al., 2013), via different histamine receptor pathways. 
The correlation between histamine and renal disease in humans comes from the observation that, 
compared to healthy subjects, plasma levels of histamine are significantly higher in patients that have 
nephrotic syndrome, end stage renal failure, and undergoing haemodialysis or peritoneal dialysis than 
in the healthy ones (Gill et al., 1991). In particular, high plasma histamine levels have been found in 
patients with renal insufficiency and uremic pruritus (Stockenhuber et al., 1990). This data is 
consistent with histamine's ability to reduce urea clearance (Bjering, 1937). Histamine may therefore 
have detrimental effects on renal function. This hypothesis is supported by a number of in vivo studies 
reported in Table 2. However, the role of histamine in renal diseases can also be hypothesised in 
terms of the presence of mast cells in several kidney diseases with a prominent fibrotic component. 
Regardless of the underlying disease, the presence of mast cells has been found to correlate with the 
progressive loss of renal function (Holdsworth and Summers, 2008). An increase in mast cells was 
found to parallel renal function in primary and secondary forms of membranous, diabetic and IgA 
nephropathy, and in allograft rejection (Roberts and Brenchley, 2000), as well as in amyloidosis, 
renovascular ischemia, reflux nephropathy, polycystic kidney disease and drug induced nephropathy 
(Holdsworth and Summers, 2008). The inhibition of mast cells has also been proposed as a possible 
target in tubulointestitial fibrosis (Li et al., 2007). Mast cells liberate a variety of well-characterized 
profibrotic mediators, including transforming growth factor (TGF)-ß. Nevertheless, histamine has 
been shown to induce a profibrotic response via H4 receptor activation. Indeed, the H4 receptor 
antagonist prototype JNJ 7777120 was found to blunt the fibrotic response by down-regulating the 
TGF-ß-Smad3/4 pathway in a model of pulmonary fibrosis induced by bleomycin, in mice (Rosa et 
al., 2014; Lucarini et al., 2016). Moreover, the H4 receptor antagonist JNJ-39758979 [pki = 7.9 
(Alexander et al., 2017)] prevented collagen deposition and fibrosis development in the kidneys of 
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diabetic animals (Pini et al., 2018). However, Kim et al. (2009) hypothesised that mast cells may 
exert a protective role in renal fibrosis secondary to obstructive uropathy in a mouse model genetically 
deficient in mast cells.  
As shown in Table 2, the majority of the publications are based on streptozotocin-induced type 1 
diabetes, which causes long term renal damage, that is consistent with diabetic nephropathy. Results 
in mice and rats were comparable, indicating that histaminergic tone is higher in diabetic animals 
than in controls (Markle et al., 1986; Gill et al., 1988; Gill et al., 1990; Rosa et al., 2013). In particular, 
HDC expression has been noted to occur in the tubular and peritubular areas in the diabetic kidney 
of mice (Pini et al., 2018). This evidence is consistent with previous studies reporting an over-activity 
of HDC. In diabetic rats the increase in renal histamine content was blunted by the administration of 
the selective HDC inhibitor alpha-hydrazinohistidine (alpha-HH) (Levine et al., 1965), but not by 
insulin (Markle et al., 1986). Based on these results, the authors proposed a possible increase in renal 
HDC activity in diabetic animals. However, being the alpha-HH administered at 25 mg/kg/day i.p. 
via an intra-abdominally implanted pump, a systemic effect could not be ruled out. The data from 
Gill et al. (1990) supported the hypothesis of an increase in renal HDC activity in diabetes. Indeed, 
comparing the HDC activity, the histamine content and the DAO activity in different tissue from 
diabetic rats, the kidney was found to be the second (aorta the first) for HDC activity and histamine 
levels, with an increase of 70 % over control. Any concomitant decrease in DAO activity was 
observed in kidney of diabetic animals. All these data are in favour of a net increase in the local 
synthesis of histamine. Besides an increase in the renal histamine content, some evidence has been 
provided in favour of a general up-regulation of the histaminergic system in the kidney of diabetic 
mice. Indeed, the immunolabeling and the gene expression analyses revealed that at least H4 receptor 
(Rosa et al., 2013) and H3 receptor (Pini et al., 2015) expression is up-regulated in the kidney of 
diabetic rats. Moreover, preliminary data report that renal H4 receptor expression parallel the 
hierarchical susceptibility to diabetic nephropathy induced by streptozotocin injection in different 
strain of mice (Gurley et al., 2006): absent in Balb/c (not susceptible), medium in C57BL/6 and higher 
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in DBA2/J (most susceptible). Also H1 receptor and H2 receptor expression was increased in diabetic 
mice from both C57BL/6 and DBA2/J strain (Pini et al., 2016a). However, the functional meaning 
of these changes is still far to be completely elucidated. Two pharmacological approaches were tested 
in the streptozotocin-induced diabetic nephropathy model: one was based on H1 receptor, while the 
other on H4 receptor antagonism (Table 2). The two strategies can be considered complementary: H1 
receptor were directed to the glomerulus and H4 receptor to the tubules, according to their localisation. 
It is currently thought that the antagonism of H1 receptor may prevent the integrity of the filtration 
barrier and reduce the mechanical damage caused by hyperglycaemia, as it is consistent with 
preserved junctional integrity at the slit diaphragm level (Veglia et al., 2016). Nevertheless, the 
detrimental effect of histamine on the filtration slit is in keeping with previous observations. In 
particular, Abboud et al. (1982), using a model of nephrosis with predominantly direct podocyte 
damage, the puromycin aminoglycoside (PAN)-induced nephrosis, stated that histamine levels are 
significantly increased in in the renal cortex of nephrotic rats. Notably, (R)-cetirizine have been 
demonstrated to reduce the focal segmental glomerulosclerosis, interstitial fibrosis and the thickening 
of the glomerular basement membrane (GBM) shown by diabetic rats, with a significant improvement 
in renal function. These changes were accompanied by a reduction in the renal inflammatory response 
(Anbar et al., 2016). On the other hand, in a model of diabetic mice, the H4 receptor antagonist JNJ-
39758979 has been demonstrated to preserve the tubular reabsortive machinery, triggering protective 
effects on glomerular integrity and a positive outcome on renal function. Once again, a reduction in 
the renal inflammatory response was observed (Pini et al., 2018). The role of histamine in 
inflammatory and immune response has long been the main subject of evaluation. However, only a 
few studies have aimed to evaluate histamine's contribution in models of renal diseases with a high 
immune component (Table 2). Notably, interesting but conflicting evidence has been reported. Two 
out of three studies on the anti-GBM-induced glomerulonephritis model failed in demonstrate an 
active role for histamine. However, in the late stage of glomerulonephritis the infiltration by histamine 
containing cells and, consequently, the histamine levels, in kidney of rats were reduced (Kossi and 
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Nahas, 2006). Moreover, both diphenhydramine and cimetidine prevented the GFR decrease, without 
influencing the anti-GBM antibodies ability to induce the glomerular pathological changes (Wilson 
et al., 1981). Therefore, the hypothesis that histamine can trigger the associated fibrotic response was 
discounted. By contrast, a study by Tanda et al. (2007) suggested that H4 receptor agonism may 
provide beneficial effects by suppressing the immune response. However, clozapine was used as the 
H4 receptor agonist [pki = 6.2 - 6.7 (Alexander et al., 2017)] in this study, but this antipsychotic drug 
binds many other different receptors, H1 receptor and H3 receptor included [pki = 8.8 - 9.6 and pki = 
5.8 for H1 receptor and H3 receptor, respectively (Alexander et al., 2017)]. Another study 
demonstrated that cyproheptadine, blocking H1 receptor, delayed the onset and reduced the degree of 
proteinuria (Bolton et al., 1974) in a model of autologous immune complex glomerulonephritis, 
which mimics human membranous glomerulopathy. These effects were, at least partially, ascribed to 
the vasoactive properties of histamine, but a partial serotonin-depended effect could not be ruled out. 
The contribute of histamine in renal haemodynamics led to evaluate its role in ischemia-induced acute 
renal failure. Almost convergent lines of evidence was provided to indicate that beneficial effects can 
be achieved following an anti-histaminergic approach. Indeed, DAO administration (0.5 U/kg i.v.) 
inhibited the induced vascular permeability, as well as preserved renal function and structure integrity 
in a model of ischemia (30 min)/reperfusion (24 h) and in another of unilaterally nephrectomy in rats. 
The combined administration of diphenhydramine and ranitidine (each at 10 mg/kg) evoked similar 
effects (Kaneko et al., 1998). Nonetheless, the histamine-release inducer compound 48/80 has been 
demonstrated to worsen kidney injury induced by bilateral renal artery and vein occlusion for 45 min, 
followed by 24 h of reperfusion. Consistently, a beneficial effect was obtained with the administration 
of cromoglicic acid (Tong et al., 2016). The suggested contribution of H2 receptor was confirmed by 
pretreating rats for 7 days with ranitidine 10 mg/kg/day in drinking water before left vascular pedicle 
clamping for 50 min in uninephrectomised animals. The drug significantly reduced the mortality at 
day 7 (Vannay et al., 2004). However, Kurata et al. (2006), obtained contrasting results as they 
demonstrated the protective effect of carnosine (15 nmol i.v.) 2-weeks after the occlusion of the left 
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renal artery and vein for 45 min. carnosine is a precursor of L-histidine and, consequently, of L-
histamine. Notably, the H3 receptor agonist (R)alpha-methylhistamine (5 pmol i.c.v.) mimicked the 
effects of carnosine, while the use of the H3 receptor antagonist thioperamide (30 nmol i.c.v.) 
abolished them (Kurata et al., 2006). The influence of H3 receptor activation in the central nervous 
system on the observed effects therefore suggests that a dichotomy may exist between peripheral and 
central histamine in the pathogenesis of ischemic renal failure. 
 
Conclusion 
In conclusion, looking at the histaminergic machinery in the kidney, it can be stated that histamine 
can act on this organ in an autocrine manner under physiological conditions, and in both an autocrine 
and paracrine manners in pathological conditions, in which either the renal inducible pool of 
histamine, or an extrarenal source, like mast cells, could occur. The presence of all four histamine 
receptors, with differential distribution, suggests and further confirms the multiple actions that 
histamine presents, but may also hint at possible histamine receptor redundancy. The overall data 
reported in the literature raise the intriguing hypothesis of redundancy between H1 receptor and H2 
receptor in renal haemodynamics; both mediating the increase in renal blood flow and reducing 
vascular resistance (Banks et al., 1978; Banks et al., 1984; Laight et al., 1995). Moreover, both H1 
receptor and H4 receptor have been demonstrated to participate in the complex process of urine 
formation, with H1 receptor mostly being involved in glomerular filtration (Anbar et al., 2016; Veglia 
et al., 2016) and H4 receptor in tubular reabsorption (Pini et al., 2018). These two receptors therefore 
appear to possess complementary function(s). However, data from the peripheral and central 
activation of the histaminergic system, H1 receptor and H3 receptor seem to present a dichotomy. The 
effect of histamine on vasopressin regulation (Bhargava et al., 1973; Selbach and Haas, 2008) against 
increases in water excretion (Sinclair et al., 1974a; Banks et al., 1978; Ichikawa and Brenner, 1979), 
as well as targeting at either peripheral or central histamine in ischemic acute renal failure, are 
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examples of this issue. These considerations should be taken into account when exploring possible 
therapeutic strategies for renal disease.  
Preclinical studies of renal injury models point out at the intriguing hypothesis of new therapeutic 
approaches directed to the histaminergic modulation in kidney diseases. However, the functional 
influence of histamine in kidney pathophysiology still needs to be completely elucidated before 
experimental data can be translated to therapeutic applications.  
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Figure legends 
Figure 1. Differential histamine receptor distribution in the mammalian nephron and collecting 
duct.  
Histamine receptors topology within the mammalian kidney based on current knowledge (Sedor and 
Abboud, 1984; Sedor and Abboud, 1985; Rosa et al., 2013; Pini et al., 2015; Veglia et al., 2015; 
Veglia et al., 2016). H1 receptor and H2 receptor have been identified within the renal corpuscle (H1 
receptor in the glomerulus and H2 receptor in glomerulus and in glomerular capsule) and in the distal 
tubule. H1 receptor and H4 receptor are both present on the renal proximal convoluted tubule. H4 
receptor is also expressed in the ascending limb of the loop of Henlé. H3 receptor have been localised 
in the collecting duct.  
Figure 2. Histamine and histamine receptor contribution to renal function.  
Proposed summary of the data reported on the effects of histamine on renal function. The amine 
mediates a range of effects through the differential contribution of all the histamine receptors. The 
increases in albuminuria, and water and salt excretion, as well as the reductions in creatinine and urea 
clearance are mediated by both H1 receptor and H4 receptor. Moreover, H1 receptor also participate 
in the reduction of the ultrafiltration coefficient as well as the modulation of renal blood flow and 
vascular resistance. The vasoactive properties of H1 receptor are shared by H2 receptor, whose 
activation also evokes renin release. The role of H2 receptor in the distal tubule is still unknown. 
Finally, H3 receptor activation may be involved in polyuria. 
